Study provides genetic evidence on new osteoporosis drug heart attack risk

New research highlights potential safety concerns around women taking romosozumab, a new anti-osteoporosis drug available on the NHS. The University of Bristol-led study, published in Arthritis& Rheumatology, analysed genetic data on nearly 34,000 people.
Source: University of Bristol news - Category: Universities & Medical Training Tags: Health, International, Research; Faculty of Health Sciences, Faculty of Health Sciences, Translational Health Sciences, Institutes, Institutes, ALSPAC, Institutes, Bristol Population Health Science Institute; Press Release Source Type: news